

Algernon Pharmaceuticals Inc.  
400 – 601 West Broadway  
Vancouver, BC V5Z 4C2

February 28, 2023

VIA SEDAR

British Columbia Securities Commission  
Alberta Securities Commission  
Financial and Consumer Affairs Authority of Saskatchewan  
The Manitoba Securities Commission  
Ontario Securities Commission  
Autorité des marchés financiers  
Financial and Consumer Services Commission (New Brunswick)  
Nova Scotia Securities Commission  
Office of the Superintendent of Securities (Prince Edward Island)  
Office of the Superintendent of Securities, Service Newfoundland and Labrador  
The Canadian Depository for Securities  
Canadian Securities Exchange

Dear Sirs/Mesdames:

**Re: Algernon Pharmaceuticals Inc. (the "Company")**

Pursuant to Policy 9 – *Name Change, Stock Splits and Share Consolidation* of the Canadian Securities Exchange, and further to the letter dated February 28, 2023 the Company advises that it will subdivide its common shares on the basis of 4 post-subdivision common shares for every 1 pre-subdivision common share (the “**Subdivision**”) held by shareholders of the Company on March 6, 2023.

The Company will push the securities required to effect the Subdivision and no new CUSIP/ISIN will be assigned to the Company’s common shares.

Sincerely,

“Christopher Moreau”  
Christopher Moreau  
Chief Executive Officer